Century Therapeutics Inc Total Assets
Century Therapeutics Inc total assets. Based on the latest financial reports, Century Therapeutics Inc (IPSC) holds total assets worth $287.01 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Century Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Century Therapeutics Inc (2015–2025)
Total assets of Century Therapeutics Inc from 2015 to 2025. This chart illustrates how Century Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Century Therapeutics Inc (IPSC) stock price for real-time trading data and today's change.
Century Therapeutics Inc - Asset Composition Analysis
Century Therapeutics Inc Total Assets Breakdown (December 2025)
Century Therapeutics Inc total assets breakdown as of December 2025. Century Therapeutics Inc's total assets of $287.01 Million consist of 54.0% current assets and 46.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.7% |
| Accounts Receivable | $667.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.20 Million | 15.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Century Therapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Century Therapeutics Inc's current assets represent 54.0% of total assets in 2025, an increase from 0.0% in 2015.
- Cash Position: Cash and equivalents constituted 27.7% of total assets in 2025, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 4.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 15.3% of total assets.
Century Therapeutics Inc Competitors by Total Assets
Key competitors of Century Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Century Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.28 | 10.72 | 15.12 |
| Quick Ratio | 8.28 | 10.72 | 15.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.70 Million | $145.22 Million | $280.53 Million |
Century Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Century Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 1.35 |
| Asset Growth Rate (YoY) | -36.7% |
| Total Assets | $223.70 Million |
| Market Capitalization | $302.40 Million USD |
Valuation Analysis
Above Book Valuation: The market values Century Therapeutics Inc's assets above their book value (1.35x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Century Therapeutics Inc's assets decreased by 36.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Century Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Century Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $223.70 Million | -36.67% |
| 2024-12-31 | $353.22 Million | -2.07% |
| 2023-12-31 | $360.69 Million | -25.87% |
| 2022-12-31 | $486.54 Million | +11.24% |
| 2021-12-31 | $437.38 Million | +309.62% |
| 2020-12-31 | $106.78 Million | +17.47% |
| 2019-12-31 | $90.90 Million | -88.01% |
| 2016-12-31 | $758.00 Million | -10.26% |
| 2015-12-31 | $844.70 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more